187 related articles for article (PubMed ID: 32576028)
1. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Magagnoli M; Carlo-Stella C; Santoro A
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
[TBL] [Abstract][Full Text] [Related]
2. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
3. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
4. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
6. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
[No Abstract] [Full Text] [Related]
7. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
[TBL] [Abstract][Full Text] [Related]
8. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
9. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Munoz J; Follows GA; Nastoupil LJ
Target Oncol; 2021 May; 16(3):295-308. PubMed ID: 33687623
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Marret G; Isambert N; Rezai K; Gal J; Saada-Bouzid E; Rolland F; Chausson M; Borcoman E; Alt M; Klijanienko J; Vansteene D; Guigay J; Kamal M; Bièche I; Le Tourneau C;
Invest New Drugs; 2021 Dec; 39(6):1641-1648. PubMed ID: 34322775
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
[TBL] [Abstract][Full Text] [Related]
12. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
14. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
15. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
[TBL] [Abstract][Full Text] [Related]
16. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
[TBL] [Abstract][Full Text] [Related]
17. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
[TBL] [Abstract][Full Text] [Related]
18. A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.
Appukkuttan S; Duchesneau E; Zichlin ML; Bhak RH; Yaldo A; Gharibo M; Babajanyan S; Duh MS
J Manag Care Spec Pharm; 2019 Apr; 25(4):437-446. PubMed ID: 30608008
[TBL] [Abstract][Full Text] [Related]
19. Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Morcos PN; Moss J; Veasy J; Hiemeyer F; Childs BH; Garmann D
Clin Pharmacol Ther; 2024 May; 115(5):1092-1104. PubMed ID: 38226495
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]